• Jesse Sussell, Emma van Eijndhoven, Taylor T Schwartz, Suzanne J Baron, Christin Thompson, Seth Clancy, and Anupam B Jena.
• Precision Health Economics, 11100 Santa Monica Blvd, Ste 500, Los Angeles, CA 90025. Email: emma.vaneijndhoven@precisionhealtheconomics.com.
• Am J Manag Care. 2020 Feb 1; 26 (2): e50-e56.

ObjectivesTo project the social value of transcatheter aortic valve replacement (TAVR) for inoperable patients with severe, symptomatic aortic stenosis (SSAS).Study DesignThis study used an economic model with parameters obtained from the literature and from US Census Bureau population projections.MethodsOur model estimated the economic value that will accrue to inoperable patients with SSAS and to device manufacturers as a result of TAVR utilization. We estimated individual patient value as the monetized gain in quality-adjusted life-years as estimated in the cost-effectiveness literature, net of device costs and cost offsets. We estimated manufacturer value by applying an assumed profit margin to revenue from device sales. We created population-level estimates by combining these individual-level estimates with age-stratified Census Bureau population projections and estimates of the incidence of AS. We assessed model uncertainty through the use of probabilistic sensitivity analyses.ResultsBetween 2018 and 2028, approximately 465,000 inoperable Americans with SSAS will be treated with TAVR. These procedures will yield a cumulative social benefit of up to $48 billion, with roughly 80% of that benefit accruing to patients and 20% accruing to device manufacturers.ConclusionsPolicy makers and payers should take this social value into account when considering decisions related to the care of inoperable patients with SSAS.

13 keywords...

hide…